Biological Products, (No Diagnostic Substances) · DE · CIK 1714899
Denali Therapeutics discovers, develops, and delivers biotherapeutics for serious diseases, including brain disorders, using proprietary barrier-crossing technology
Comparable business profile · signals at a glance
In the 90 days to Jan 6, 2026: 2 sold $865K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Jan 6, 2026 | Watts Ryan J.President and CEO | Sell | 35,198 | $16.50 | $581K |
| Jan 6, 2026 | Schuth Alexander O.COFO and Secretary | Sell | 17,218 | $16.50 | $284K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Reputable outlets only (Reuters, WSJ, CNBC, Barron's, and peers). More on Google News ↗